Ablatherm Integrated Imaging High Intensity Focused Ultrasound for the Indication of Low Risk, Localized...
Prostate CancerThe purpose of this study is to determine the substantial equivalence of the Ablatherm high intensity focused ultrasound (HIFU) as compared to cryotherapy for the treatment of low risk, localized prostate cancer.
Investigation of Early Hormonotherapy Efficacy of Prostate Cancer
Prostate CancerThe purpose of this study is to determine whether early hormonotherapy is effective in the treatment of high risk prostate cancer patients after radical prostatectomy.
Biological Imaging for Optimising Clinical Target Volume (CTV) and Gross Tumour Volume (GTV) Contouring...
Prostate CancerThe clinical outcome after external beam irradiation for prostate cancer is disappointing in the advanced tumor stages. There are indications that an increase in radiation dose to the tumor will improve outcome significantly, especially to the biologically active tumour parts within the cancer area. Until recently no imaging equipment was available to define both the anatomic and biologically active tumor parts. Now, at the Center for Biological Imaging and Adaptive Radiotherapy, equipment is at hand that will be able to visualise the areas mentioned above. When combining the data of these imaging modalities it might be possible to create an optimised irradiation plan. This study is a planning study in which, on 15 patients, the different anatomical and biological imaging data per patient will be evaluated, matched and finally a theoretical improved irradiation treatment plan will be made. This research complies with the current opinion on radiation development. Progress in functional imaging is likely to provide the tools required for individualised risk-adapted radiotherapy.
Long Acting LHRH Versus Short Acting LHRH in the Treatment of Prostate Cancer
Prostate CancerBrachytherapy, or Transperineal implantation of the prostate (TPIP), is a recognized form of treatment for localized cancer of the prostate. TPIP has been used at the British Columbia Cancer Agency (BCCA) since 1998. As part of the treatment, some patients also require hormone therapy for 6 months. This is given as injections of a drug called an LHRH agonist. The LHRH agonist is made either as short-acting (1-month) or long-acting (3 month) injections. The LHRH agonist lowers testosterone levels, which helps make delivery of TPIP easier, and more effective. There are specific guidelines regarding the use of LHRH agonist treatment with brachytherapy, however there is no policy whether short-acting or long-acting LHRH agonists should be used. Analysis of results from BC has shown that there seems to be a delay in the time in which testosterone levels return to normal in men who receive the long-acting LHRH agonist compared with the short-acting LHRH agonist, however this is not known for sure.
ASCENT: Androgen Independent Prostate Cancer Study of Calcitriol Enhancing Taxotere
Prostate CancerThe purposes of this study are to determine if DN-101 plus Taxotere lowers PSA levels, delays or limits disease progression and is safe with minimal side effects.
Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer
Prostate CancerRATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of combination chemotherapy in treating patients with advanced prostate cancer.
A Pilot Study of Hormonal Therapy Combined With Central Memory T Cells (Tcm) for Patients With Advanced...
Prostatic NeoplasmsThe purpose of this study is to evaluate the feasibility, safety and oncological efficacy of hormonal therapy combined with autologous Tcm cells for patients with advanced prostate cancer.
Evaluating Race Specific AGE Accumulation as a Behavioral Biomarker Prostate Cancer Survivors
Prostate CancerThe purpose of this study is to show that reduction in advanced glycation end-products (AGEs) is associated with the beneficial regulation of receptor for AGE (RAGE) mediated tumor response which may correlate with improved quality of life in PCa survivors. AGEs are produced by the body and are affected by lifestyle, weight and diet.
Gallium-68 PSMA-11 PET in Participants With Prostate Cancer
Metastatic Prostate CarcinomaRecurrent Prostate Carcinoma3 moreThis phase II trial studies how well gallium-68 PSMA-11 PET/CT or PET/MRI works in finding prostate cancer cells that have come back (recurrent) in patients with prostate cancer. Gallium-68 PSMA-11 is a type of radioactive compound, called a radiotracer, which is injected in the vein and can accumulate in tumor cells to generate a signal detected by PET/CT or PET/MRI imaging. This may help researchers in finding recurrent prostate cancer cells in patients with prostate cancer.
MBM-02 (Tempol) for the Treatment of Biochemical Recurrent Prostate Cancer
Prostate Cancer RecurrentBiochemical Recurrent Prostate CancerThis is an open label trial to assess the efficacy of MBM-02 (Tempol) as a treatment for patients diagnosed with prostate cancer in biochemical recurrence.